Organ transplant preservation company Paragonix Technologies is launching the first FDA-cleared system for protecting donated pancreas tissue.

Roche has filed a lawsuit against Stanford University and its spinout Foresight Diagnostics, saying the young cancer test developer was built upon trade secrets it acquired for detecting tumor DNA in the bloodstream.

Radiopharmaceutical company Pentixapharm is picking up fellow Germany-based Glycotope’s target discovery unit for an undisclosed sum in order to double its pipeline courtesy of a portfolio of preclinical cancer antibodies.

The FDA has greenlit its first point-of-care diagnostic test for hepatitis C, capable of using only a fingerstick blood sample, in a bid to quickly connect patients with antiviral drugs.

Crosswalk Therapeutics has strolled over to Codexis to pick up Fabry and Pompe disease compounds that remain from an abandoned Takeda gene therapy collaboration.

Annovis Bio has published its delayed phase 3 Parkinson’s disease data, reporting success in subgroups and secondary endpoints while skirting the question of whether the candidate moved the needle on the main goal.

Cartesian Therapeutics has claimed a phase 2b win for its BCMA-directed CAR-T therapy in generalized myasthenia gravis (gMG). But the biotech’s victory came on a primary endpoint it changed in May and in a population that excluded the 25% of participants treated at community clinics.

Mouse models of GBA1 Parkinson’s disease that are treated with Gain Therapeutics’ clinical-stage drug appear to have better cognitive function and lower disease biomarkers than untreated animals.

Issues with ventilators across three major manufacturers—Philips, Baxter and Zoll—have led to a string of Class I recall notices from the FDA, the agency’s most severe level.

Merck & Co. is expanding a research partnership with Orion into an exclusive licensing pact, putting more than $1.6 billion biobucks on the table for cancer candidates targeting CYP11A1, an enzyme important in steroid production.